Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18173033 | 1.00 | KDM1A (0.65) | KDM1AHDAC6LMNAGAAMAOB | |
| SCHEMBL21049041 | 0.87 | KDM1A (0.63) | KDM1AHDAC6MAOBHDAC1HDAC8 | |
| SCHEMBL18182726 | 0.87 | KDM1A (0.63) | KDM1AHDAC6MAOBHDAC1HDAC8 | |
| SCHEMBL18172555 | 0.85 | KDM1A (0.47) | KDM1AHDAC6MAOB | |
| SCHEMBL18172552 | 0.85 | KDM1A (0.47) | KDM1AHDAC6MAOB | |
| SCHEMBL18182658 | 0.85 | KDM4E (0.57) | KDM1AHDAC6 | |
| SCHEMBL21049103 | 0.84 | KDM1A (0.60) | KDM1AHDAC6MAOBHDAC1HDAC8 | |
| SCHEMBL18182725 | 0.84 | KDM1A (0.60) | KDM1AHDAC6MAOBHDAC1HDAC8 | |
| SCHEMBL21088917 | 0.82 | KDM1A (0.57) | KDM1AHDAC6MAOBHDAC1HDAC8 | |
| SCHEMBL18182137 | 0.81 | KDM1A (0.65) | KDM1AHDAC6MAOBHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
| EP-3286172-A1 | LSD1 INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172496-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | KDM1B, KDM1A, KDM2A | KDM1A 2/4885HDAC6 96/4885LMNA 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.